Literature DB >> 32875484

Validation and update of the minimal risk tool in patients suspected of chronic coronary syndrome.

Laust Dupont Rasmussen1, Louise Nissen2, Jelmer Westra3, Lars Lyhne Knudsen2, Lene Helleskov Madsen2, Niels Ramsing Holm3, Evald Høj Christiansen3, Hans Erik Bøtker3, Morten Bøttcher2, Simon Winther2.   

Abstract

Risk stratification in patients with suspected coronary artery disease (CAD) is important. Recently, the minimal-risk-tool (MRT) was developed to identify individuals with low CAD risk despite symptoms in order to avoid unnecessary testing. We aimed to validate and update the MRT-model in a contemporary cohort. The Dan-NICAD trial cohort, consisting of 1675 consecutive patients referred for coronary computed tomography angiography (CTA), was used to calculate the MRT-score based on the published fitted variable coefficients from the PROMISE and SCOT-HEART trials. Minimal risk was defined as zero calcium score, no coronary atherosclerosis at coronary CTA, and no cardiovascular events in the follow-up period. We tested an updated MRT-model by pooling the fitted variable coefficients from all three trials. A total of 1544 patients fulfilling the inclusion criteria were followed for 3.1 [2.7-3.4] years. In 710 (46%) patients, the criteria for minimal risk were fulfilled. Despite substantial coefficient variation, the MRTs based on the PROMISE, the SCOT-HEART and the updated MRT variables showed similar moderate to high discriminative performance for minimal risk estimation. Although all three models tended to underestimate minimal risk, the updated MRT had the best performance. Using a 75% minimal risk cut-off, the updated MRT showed a sensitivity of 11.6% (95% CI 9.3-14.2%) and specificity of 99.3% (95% CI 98.6-99.8%). An updated MRT model based on three large studies increased calibration compared to the existing MRT models, whereas discrimination was similar despite substantial coefficient variation. The updated MRT might supplement currently recommended pre-test probability models.

Entities:  

Keywords:  Coronary artery disease; Minimal risk; Pre-test probability

Mesh:

Year:  2020        PMID: 32875484     DOI: 10.1007/s10554-020-01982-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  3 in total

1.  The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial.

Authors:  Michael G Nanna; Sreekanth Vemulapalli; Christopher B Fordyce; Daniel B Mark; Manesh R Patel; Hussein R Al-Khalidi; Michelle Kelsey; Beth Martinez; Eric Yow; Sarah Mullen; Gregg W Stone; Ori Ben-Yehuda; James E Udelson; Campbell Rogers; Pamela S Douglas
Journal:  Am Heart J       Date:  2021-12-23       Impact factor: 4.749

2.  Comparison of Risk Assessment Strategies for Patients with Diabetes Mellitus and Stable Chest Pain: A Coronary Computed Tomography Angiography Study.

Authors:  Jia Zhao; Shuo Wang; Pengyu Zhao; Yong Huo; Chunjie Li; Jia Zhou
Journal:  J Diabetes Res       Date:  2022-01-25       Impact factor: 4.011

3.  Predictive Added Value of Selected Plasma Lipids to a Re-estimated Minimal Risk Tool.

Authors:  Antonella Bodini; Elena Michelucci; Nicoletta Di Giorgi; Chiara Caselli; Giovanni Signore; Danilo Neglia; Jeff M Smit; Arthur J H A Scholte; Pierpaolo Mincarone; Carlo G Leo; Gualtiero Pelosi; Silvia Rocchiccioli
Journal:  Front Cardiovasc Med       Date:  2021-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.